LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | Mitoxantrone | 3.33 | uM | LJP5 | 1 | C20 | 72 | hr | 1097 | 665 | 3769 | 0.1764 | -0.1618 |
BT-20 | Mitoxantrone | 3.33 | uM | LJP5 | 2 | C20 | 72 | hr | 1097 | 777 | 3769 | 0.2061 | -0.1198 |
BT-20 | Mitoxantrone | 3.33 | uM | LJP5 | 3 | C20 | 72 | hr | 1097 | 632 | 3769 | 0.1677 | -0.1741 |
BT-20 | Mitoxantrone | 3.33 | uM | LJP6 | 1 | C20 | 72 | hr | 1097 | 753 | 3769 | 0.1998 | -0.1288 |
BT-20 | Mitoxantrone | 3.33 | uM | LJP6 | 2 | C20 | 72 | hr | 1097 | 621 | 3769 | 0.1647 | -0.1782 |
BT-20 | Mitoxantrone | 3.33 | uM | LJP6 | 3 | C20 | 72 | hr | 1097 | 599 | 3769 | 0.1589 | -0.1865 |
BT-20 | MK2206 | 3.33 | uM | LJP6 | 1 | F02 | 72 | hr | 1097 | 1810 | 3769 | 0.4802 | 0.2667 |
BT-20 | MK2206 | 3.33 | uM | LJP6 | 2 | F02 | 72 | hr | 1097 | 1712 | 3769 | 0.4542 | 0.2300 |
BT-20 | MK2206 | 3.33 | uM | LJP6 | 3 | F02 | 72 | hr | 1097 | 1599 | 3769 | 0.4242 | 0.1878 |
BT-20 | Neratinib | 3.33 | uM | LJP5 | 1 | A14 | 72 | hr | 1097 | 1496 | 3769 | 0.3969 | 0.1492 |
BT-20 | Neratinib | 3.33 | uM | LJP5 | 2 | A14 | 72 | hr | 1097 | 1632 | 3769 | 0.4329 | 0.2001 |
BT-20 | Neratinib | 3.33 | uM | LJP5 | 3 | A14 | 72 | hr | 1097 | 2016 | 3769 | 0.5348 | 0.3438 |
BT-20 | Nilotinib | 3.33 | uM | LJP5 | 1 | N14 | 72 | hr | 1097 | 3622 | 3769 | 0.9609 | 0.9448 |
BT-20 | Nilotinib | 3.33 | uM | LJP5 | 2 | N14 | 72 | hr | 1097 | 3770 | 3769 | 1.0001 | 1.0002 |
BT-20 | Nilotinib | 3.33 | uM | LJP5 | 3 | N14 | 72 | hr | 1097 | 3811 | 3769 | 1.0110 | 1.0155 |
BT-20 | Nintedanib | 3.33 | uM | LJP6 | 1 | H02 | 72 | hr | 1097 | 2686 | 3769 | 0.7126 | 0.5945 |
BT-20 | Nintedanib | 3.33 | uM | LJP6 | 2 | H02 | 72 | hr | 1097 | 2750 | 3769 | 0.7295 | 0.6185 |
BT-20 | Nintedanib | 3.33 | uM | LJP6 | 3 | H02 | 72 | hr | 1097 | 2440 | 3769 | 0.6473 | 0.5025 |
BT-20 | NU7441 | 3.33 | uM | LJP5 | 1 | C08 | 72 | hr | 1097 | 3115 | 3769 | 0.8264 | 0.7551 |
BT-20 | NU7441 | 3.33 | uM | LJP5 | 2 | C08 | 72 | hr | 1097 | 2809 | 3769 | 0.7452 | 0.6406 |
BT-20 | NU7441 | 3.33 | uM | LJP5 | 3 | C08 | 72 | hr | 1097 | 3220 | 3769 | 0.8542 | 0.7944 |
BT-20 | Dactolisib | 3.33 | uM | LJP5 | 1 | M14 | 72 | hr | 1097 | 1376 | 3769 | 0.3650 | 0.1043 |
BT-20 | Dactolisib | 3.33 | uM | LJP5 | 2 | M14 | 72 | hr | 1097 | 1313 | 3769 | 0.3483 | 0.0807 |
BT-20 | Dactolisib | 3.33 | uM | LJP5 | 3 | M14 | 72 | hr | 1097 | 1196 | 3769 | 0.3173 | 0.0370 |
BT-20 | NVP-TAE684 | 3.33 | uM | LJP6 | 1 | K14 | 72 | hr | 1097 | 1463 | 3769 | 0.3881 | 0.1369 |